In CSF of AD cohorts, soluble TREM2 levels were reported to increase over the course of the disease, reaching a peak during the early-phase stages [151], possibly reflecting an initial immune response to the deposition of pathological aggregates. Here, TREM2 is linked to Alzheimer disease.